Updated on 2025/08/22

写真a

 
SASAKI Takanori
 
Organization
School of Medicine Department of Oral Surgery Lecturer
Title
Lecturer
External link

Research Areas

  • Life Science / Surgical dentistry

Papers

  • 頬部に発生した巨大な神経鞘腫の1例

    平川 結, 宮本 昇, 佐々木 敬則, 笹谷 聖, 都倉 尭明, 大橋 伸英, 荻 和弘, 出張 裕也, 宮崎 晃亘

    日本口腔科学会雑誌   73 ( 3 )   262 - 262   2024.9

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    researchmap

  • Notch signaling genes and CD8+ T-cell dynamics: Their contribution to immune-checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective study. International journal

    Kazuhiro Ogi, Takahiro Iwamoto, Takashi Sasaya, Koyo Nishiyama, Takaaki Tokura, Takanori Sasaki, Hironari Dehari, Yohei Arihara, Kazuyuki Murase, Masato Saito, Masanori Someya, Kohichi Takada, Akihiro Miyazaki

    Cancer medicine   13 ( 5 )   e6985   2024.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Aberrant Notch signaling pathway has been related with the tumorigenesis in head and neck region, involving oral cavity. Here, we report the correlation between mutations in the Notch signaling pathway and CD8+ T-cell infiltration via PD-L1, which lead to enhanced antitumor immunity and may target for immune-checkpoint inhibitors (ICIs) therapy. METHODS: This retrospective study analyzed the results of immunohistochemical staining for PD-L1 and CD8+ T-cell infiltration in 10 patients and whole-exome sequencing (WES) was conducted on five of these patients to identify frequently mutated genes. RESULTS: Four of 10 patients were positive for PD-L1 and CD8+ T. By analyzing WES in three of these four patients, we notably identified the mutations of NOTCH1, FBXW7, and noncoding RNA intronic mutation in NOTCH2NLR in two of these three patients. This study may enable better selection of ICI therapy with CD8+ T-cell infiltration via PD-L1 expression for oral squamous cell carcinoma patients with mutations in Notch signaling pathway.

    DOI： 10.1002/cam4.6985

    PubMed

    researchmap

  • 広範囲顎骨支持型補綴治療における当科での非可動粘膜獲得のための一工夫

    都倉 尭明, 出張 裕也, 西山 廣陽, 宮本 昇, 大橋 伸英, 佐々木 敬則, 宮崎 晃亘

    Japanese Journal of Maxillo Facial Implants   22 ( 3 )   177 - 177   2023.11

    　More details

    Language：Japanese   Publisher：(公社)日本顎顔面インプラント学会  

    Ichushi

    researchmap

  • Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.

    Yutaro Ikeuchi, Masanori Someya, Tomokazu Hasegawa, Masato Saito, Shoh Mafune, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Yoshihiko Hirohashi, Toshihiko Torigoe, Naoki Hirokawa, Akihiro Miyazaki, Koh-Ichi Sakata

    Medical molecular morphology   2023.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of proteins involved in tumor immunity on the outcomes of combined IACRT and surgery for oral cancer. We examined CD8 + and FoxP3 + tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on immune cells and tumor cells in pretreatment biopsy samples from 69 patients diagnosed with oral cancer treated with IACRT at our institution during 2000-2020. Patients with abundant CD8 + TILs had significantly better 5-year disease-specific survival (DSS) compared to that of patients with less infiltration of these cells (P = 0.016). Patients with higher FoxP3 + T-cells invasion had significantly better DSS compared to that of less FoxP3 (P = 0.005). Patients with high PD-L1 expression in tumor cells and immune cells had significantly better DSS than that of patients with low PD-L1 expression in these cells (P = 0.009 and P = 0.025, respectively). Collectively, these results suggest that the tumor immune microenvironment could affect outcomes of IACRT treatment in oral cancer.

    DOI： 10.1007/s00795-023-00367-8

    PubMed

    researchmap

  • Accurate estimation of skeletal muscle mass by comparison of computed tomographic images of the third lumbar and third cervical vertebrae in Japanese patients with oral squamous cell carcinoma.

    Nobuhide Ohashi, Kazushige Koike, Kurumi Sakai, Koyo Nishiyama, Takanori Sasaki, Kazuhiro Ogi, Hironari Dehari, Nobumichi Kobayashi, Akihiro Miyazaki

    Oral radiology   39 ( 2 )   408 - 417   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: We evaluated the accuracy of estimating the cross-sectional area (CSA) at the third lumbar vertebra (L3) based on the CSA at the third cervical vertebra (C3) using computed tomographic images, and we identified the sources of error and bias using the evaluation of absolute reliability in 89 Japanese patients with oral squamous cell carcinoma. METHODS: Skeletal muscle CSA was measured at the C3 and L3 on pretreatment computed tomographic images. We used the CSA at the C3 to estimate CSA at the L3 in an existing prediction formula. Correlation coefficients were used to evaluate the relative reliability of the estimate, and Bland-Altman analysis and minimum detectable change (MDC) were used to evaluate its absolute reliability. RESULTS: Estimated and actual CSAs at L3 were strongly correlated (r = 0.885, p < 0.001). The mean difference between the estimated and actual CSAs was - 1.0887 cm2, the 95% confidence interval was - 4.09 to 1.91 cm2 (p = 0.472), and the 95% limits of agreement were - 29.0 and 26.8 cm2. The MDC at the 95% level of confidence in estimated and actual CSAs was 27.9 cm2. CONCLUSIONS: The estimation of CSA at the L3 from the existing prediction formula with the CSA at the C3 had no systematic biases, but it did have random errors. Random errors resulted from measurement errors and biological variation. Usefulness of the existing formula is limited by physical differences in populations.

    DOI： 10.1007/s11282-022-00653-8

    PubMed

    researchmap

  • Clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer

    Kazushige Koike, Nobuhide Ohashi, Koyo Nishiyama, Junya Okamoto, Takanori Sasaki, Kazuhiro Ogi, Hironari Dehari, Naoki Hirokawa, Masanori Someya, Masato Saito, Hiroki Okuda, Akemi Otani, Tomoko Sonoda, Taro Sugawara, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Koh-Ichi Sakata, Akihiro Miyazaki

    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY   134 ( 3 )   347 - 353   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.oooo.2022.04.042

    Web of Science

    researchmap

  • Clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer. International journal

    Kazushige Koike, Nobuhide Ohashi, Koyo Nishiyama, Junya Okamoto, Takanori Sasaki, Kazuhiro Ogi, Hironari Dehari, Naoki Hirokawa, Masanori Someya, Masato Saito, Hiroki Okuda, Akemi Otani, Tomoko Sonoda, Taro Sugawara, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Koh-Ichi Sakata, Akihiro Miyazaki

    Oral surgery, oral medicine, oral pathology and oral radiology   134 ( 3 )   347 - 353   2022.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: The aim of this study was to examine the clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy (IACRT) using cisplatin in combination with oral S-1 (tegafur/gimeracil/oteracil potassium) on stage III and IV oral squamous cell carcinoma. STUDY DESIGN: Thirty patients received infusions of superselective intra-arterial cisplatin 60 mg/m2 by the Seldinger method and conventional external beam radiotherapy (total 40 Gy) combined with oral S-1 on the day of irradiation. Curative surgery and neck dissection were performed 4 to 6 weeks after IACRT. The clinical response of the primary lesion was evaluated approximately 4 weeks after IACRT. The surgically resected specimens were examined for histologic features according to the grading system for histologic evaluation and for residual tumor grade (RGrades). RESULTS: Histopathologic evaluation of the therapeutic effect was grade 2 in 10 patients and grade 3 in 16 patients. According to the distribution of RGrades, the remaining tumor cells were mostly in the central area of the primary lesion, as seen in 24 patients. CONCLUSIONS: These findings indicate that neoadjuvant IACRT with cisplatin and oral S-1 was an effective treatment, suggesting the possibility of reducing the extent of curative surgery based on RGrades.

    DOI： 10.1016/j.oooo.2022.04.042

    PubMed

    researchmap

  • Prognostic Value of CD45Ro+ T-Cell Expression in Patients With Oral Squamous Cell Carcinoma. International journal

    Kazushige Koike, Koyo Nishiyama, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Shota Shimizu, Takashi Sasaya, Kei Tsuchihashi, Tomoko Sonoda, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Akihiro Miyazaki

    Anticancer research   41 ( 9 )   4515 - 4522   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND/AIM: The role of tumour-infiltrating CD45Ro+ T-cells in oral squamous cell carcinoma (OSCC) is unclear. This study aimed to evaluate prognostic biomarkers for OSCC. PATIENTS AND METHODS: We determined the density of tumour-infiltrating CD45Ro+ T cells in the parenchyma and stroma at the tumour centre (TCe) and invasive front (IF) and examined the association between the density of these cells and histopathological status in 142 patients. RESULTS: Five-year overall survival (OS) and recurrence-free survival were favourable in patients with high CD45Ro+ T-cell density in the TCe stroma. OS was favourable in patients with high CD45Ro+ T-cell density in the IF stroma. Stepwise Cox regression model analysis indicated that CD45Ro+ T-cells in the stroma of the IF and TCe were an independent prognostic factor for OS. CONCLUSION: CD45Ro+ T-cells in the stroma of the IF and TCe play a role in cancer immune surveillance and may be a useful prognostic factor.

    DOI： 10.21873/anticanres.15262

    PubMed

    researchmap

  • 当院における周術期等口腔機能管理の臨床統計的検討

    上野 智史, 小池 和茂, 土橋 恵, 笹谷 聖, 西山 廣陽, 大西 みちよ, 中井 裕美, 上田 愛, 佐々木 敬則, 三木 善樹, 高橋 ゆかり, 水野 愛理, 種村 理絵子, 荻 和弘, 出張 裕也, 宮崎 晃亘

    日本口腔ケア学会雑誌   14 ( 3 )   199 - 199   2020.9

    　More details

    Language：Japanese   Publisher：(一社)日本口腔ケア学会  

    Ichushi

    researchmap

  • Prognostic value of HLA class I expression in patients with oral squamous cell carcinoma. International journal

    Kazushige Koike, Hironari Dehari, Shota Shimizu, Koyo Nishiyama, Tomoko Sonoda, Kazuhiro Ogi, Junichi Kobayashi, Takanori Sasaki, Takashi Sasaya, Kei Tsuchihashi, Tomohide Tsukahara, Tadashi Hasegawa, Toshihiko Torigoe, Hiroyoshi Hiratsuka, Akihiro Miyazaki

    Cancer science   111 ( 5 )   1491 - 1499   2020.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Human leukocyte antigen (HLA) class Ⅰ molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class Ⅰ expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5-year overall survival and disease-specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class Ⅰ expression at the tumor invasive front and could be a prognostic factor for OSCC.

    DOI： 10.1111/cas.14388

    PubMed

    researchmap

  • Prognostic value of FoxP3 and CTLA-4 expression in patients with oral squamous cell carcinoma. International journal

    Kazushige Koike, Hironari Dehari, Kazuhiro Ogi, Shota Shimizu, Koyo Nishiyama, Tomoko Sonoda, Takanori Sasaki, Takashi Sasaya, Kei Tsuchihashi, Tadashi Hasegawa, Toshihiko Torigoe, Hiroyoshi Hiratsuka, Akihiro Miyazaki

    PloS one   15 ( 8 )   e0237465   2020

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Tumor-infiltrating lymphocytes include tumor-reactive lymphocytes and regulatory T-cells. However, the prognostic value of tumor-infiltrating lymphocytes in oral squamous cell carcinoma (OSCC) remains unclear. METHODS: We used immunohistochemistry to evaluate the presence of tumor-infiltrating FoxP3⁺ T-cells and CTLA-4⁺ cells in four distinct histological compartments (tumor parenchyma and stroma at the tumor center, and parenchyma and stroma at the invasive front) and assessed the association between the prevalence of these cells and the histopathological status of 137 patients with OSCC. RESULTS: Five-year overall survival, disease-specific survival, and recurrence-free survival were favorable in patients with high numbers of FoxP3⁺ T-cells in the parenchyma of the invasive front. Recurrence-free survival and metastasis-free survival were decreased in patients with high numbers of CTLA-4⁺ cells in the parenchyma of the invasive front. CONCLUSIONS: The presence of FoxP3⁺ T-cells in the parenchyma of the invasive front may be a useful prognostic factor. Our results indicate that FoxP3⁺ T-cells may exert site-specific anti-tumor effects but may not play an immunosuppressive role in OSCC. In addition, our results suggest that CTLA-4+ cells suppress the function of FoxP3+ T-cells and promote anti-tumor immunity in OSCC.

    DOI： 10.1371/journal.pone.0237465

    PubMed

    researchmap

  • Induction and Analysis of Cytotoxic T-Lymphocytes that Recognize Autologous Oral Squamous Cell Carcinoma Reviewed

    Jun-Ya Okamoto, Akihiro Miyazaki, Jun-Ichi Kobayashi, Sho Miyamoto, Takanori Sasaki, Takayuki Kanaseki, Yoshihiko Hirohashi, Toshihiko Torigoe, Hiroyoshi Hiratsuka

    ANTICANCER RESEARCH   37 ( 9 )   4889 - 4897   2017.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.21873/anticanres.11898

    PubMed

    Web of Science

    researchmap

  • Hypoxia-induced epithelial-mesenchymal transition is regulated by phosphorylation of GSK3-beta via PI3 K/Akt signaling in oral squamous cell carcinoma Reviewed

    Takeshi Kaneko, Hironari Dehari, Takanori Sasaki, Tomohiro Igarashi, Kazuhiro Ogi, Jun-ya Okamoto, Mayumi Kawata, Jun-ichi Kobayashi, Akihiro Miyazaki, Kenji Nakamori, Hiroyoshi Hiratsuka

    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY   122 ( 6 )   719 - 730   2016.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.oooo.2016.06.008

    PubMed

    Web of Science

    researchmap

  • A case of surgical treatment of mandibular condylar fracture with facial nerve paralysis

    Masato Abe, Akihiro Miyazaki, Mitsuyoshi Nakai, Tomohiro Igarashi, Jun-ichi Kobayashi, Akira Yorozu, Takanori Sasaki, Mayumi Kawata, Hironari Dehari, Kazuhiro Ogi, Hiroyoshi Hiratsuka

    Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology   28 ( 4 )   324 - 327   2016.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier Ltd  

    DOI： 10.1016/j.ajoms.2016.02.002

    researchmap

  • Microenvironmental stresses induce HLA-E/Qa-1 surface expression and thereby reduce CD8(+) T-cell recognition of stressed cells Reviewed

    Takanori Sasaki, Takayuki Kanaseki, Yosuke Shionoya, Serina Tokita, Sho Miyamoto, Eri Saka, Vitaly Kochin, Akira Takasawa, Yoshihiko Hirohashi, Yasuaki Tamura, Akihiro Miyazaki, Toshihiko Torigoe, Hiroyoshi Hiratsuka, Noriyuki Sato

    EUROPEAN JOURNAL OF IMMUNOLOGY   46 ( 4 )   929 - 940   2016.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/eji.201545835

    PubMed

    Web of Science

    researchmap

  • Small proline-rich protein-1B is overexpressed in human oral squamous cell cancer stem-like cells and is related to their growth through activation of MAP kinase signal Reviewed

    Yoshitaka Michifuri, Yoshihiko Hirohashi, Toshihiko Torigoe, Akihiro Miyazaki, Jyunki Fujino, Yasuaki Tamura, Tomohide Tsukahara, Takayuki Kanaseki, Junichi Kobayashi, Takanori Sasaki, Akari Takahashi, Kenji Nakamori, Akira Yamaguchi, Hiroyoshi Hiratsuka, Noriyuki Sato

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   439 ( 1 )   96 - 102   2013.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbrc.2013.08.021

    PubMed

    Web of Science

    researchmap

  • High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis Reviewed

    Yoshitaka Michifuri, Yoshihiko Hirohashi, Toshihiko Torigoe, Akihiro Miyazaki, Junichi Kobayashi, Takanori Sasaki, Jyunki Fujino, Hiroko Asanuma, Yasuaki Tamura, Kenji Nakamori, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Noriyuki Sato

    PATHOLOGY INTERNATIONAL   62 ( 10 )   684 - 689   2012.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.1440-1827.2012.02851.x

    PubMed

    Web of Science

    researchmap

  • Clinical Significance of Computed Tomographic Assessment and Anatomic Features of the Inferior Alveolar Canal as Risk Factors for Injury of the Inferior Alveolar Nerve at Third Molar Surgery Reviewed

    Megumi Ueda, Kenji Nakamori, Kaori Shiratori, Tomohiro Igarashi, Takanori Sasaki, Naoki Anbo, Takeshi Kaneko, Naohiro Suzuki, Hironari Dehari, Tomoko Sonoda, Hiroyoshi Hiratsuka

    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY   70 ( 3 )   514 - 520   2012.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.joms.2011.08.021

    PubMed

    Web of Science

    researchmap

  • Survivin-2B peptide vaccine therapy for patients with oral cancer : Phase I clinical trial

    MIYAZAKI Akihiro, KOBAYASHI Junichi, YAMAMOTO Takashi, MICHIFURI Yoshitaka, SASAKI Takanori, NAKAMORI Kenji, HIROHASHI Yoshihiko, TORIGOE Toshihiko, SATO Noriyuki, HIRATSUKA Hiroyoshi

    Journal of Japanese Society of Oral Oncology   23 ( 4 )   117 - 122   2011.12

    　More details

    Language：Japanese   Publisher：Japanese Society of Oral Oncology  

    Survivin, an inhibitor of apoptosis protein (IAP), is abundantly expressed in most malignancies, but is hardly detectable in normal adult tissues. We previously reported that survivin was an ideal cancer antigen, and that the survivin-2B-derived peptide, survivin-2B80-88 (AYACNTSTL), could induce a cytotoxic T lymphocyte (CTL) response in the context of HLA-A24. Based on these findings, to assess its safety and efficacy, in September 2003 we performed a clinical trial using the peptide alone on patients with advanced or recurrent oral cancer. Vaccinations were administered six times at 14-day intervals. The results indicated that survivin-2B peptide vaccination was safe and had therapeutic potential for oral cancer patients. A subsequent clinical trial of the peptide in combination with incomplete Freund's adjuvant (IFA) and interferon (IFN)-α was commenced in September 2006. The survivin-2B peptide plus IFA vaccination was administered four times at 14-day intervals in combination with IFN-α, which was administered once or twice a week. To date, no severe adverse events have been observed. The results of this trial suggest that the survivin-2B peptide and IFA vaccination in combination with IFN-α induced the peptide specific CTL more effectively than the peptide alone, and that the vaccination was tolerated well by patients. This regimen may be useful as a new therapeutic modality for patients with oral cancer.

    Other Link： http://search.jamas.or.jp/link/ui/2012099849

    DOI： 10.5843/jsot.23.117

    researchmap

  • Clinical investigation of bisphosphonate-related osteonecrosis of the jaws Reviewed

    Hironari Dehari, Kei Tomihara, Megumi Ueda, Makoto Shimanishi, Masayuki Ono, Takanori Sasaki, Tomohiro Igarashi, Kaori Shiratori, Masato Abe, Kazuhiro Ogi, Kenji Nakamori, Akihiro Miyazaki, Itaru Nagai, Hiroyoshi Hiratsuka

    Japanese Journal of Cancer and Chemotherapy   36 ( 13 )   2587 - 2592   2009

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Japanese Journal of Cancer and Chemotherapy Publishers Inc.  

    PubMed

    researchmap

▼display all

MISC

  • 第VII因子欠乏症患者に対して顎矯正手術を行った1例

    都倉 尭明, 出張 裕也, 桜田 奈保, 橋 雄馬, 木山 望, 上田 愛, 大橋 伸英, 佐々木 敬則, 宮崎 晃亘

    日本顎変形症学会雑誌   34 ( 2 )   114 - 114   2024.5

    　More details

    Language：Japanese   Publisher：(NPO)日本顎変形症学会  

    Ichushi

    researchmap

  • 超高齢者に発症した下顎骨骨髄炎に起因する壊死性筋膜炎の1例

    榎本 隆久, 佐々木 敬則, 大和田 哲志, 桜田 奈保, 上野 智史, 都倉 尭明, 岡本 準也, 荻 和弘, 出張 裕也, 宮崎 晃亘

    日本口腔科学会雑誌   73 ( 1 )   38 - 38   2024.3

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    researchmap

  • NOTCHシグナル伝達系の遺伝子変異は,再発口腔癌における免疫チェックポイント阻害剤の治療効果に影響する

    荻 和弘, 岩本 空大, 笹谷 聖, 都倉 尭明, 佐々木 敬則, 平塚 博義, 宮崎 晃亘

    頭頸部癌   49 ( 2 )   156 - 156   2023.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • ProPlan CMFを用いた,簡便な3Dサージカルガイドの作製の試み

    都倉 尭明, 出張 裕也, 橋 雄馬, 木山 望, 上田 愛, 大橋 伸英, 佐々木 敬則, 宮崎 晃亘

    日本顎変形症学会雑誌   33 ( 2 )   154 - 154   2023.5

    　More details

    Language：Japanese   Publisher：(NPO)日本顎変形症学会  

    Ichushi

    researchmap

  • Clinical study of preoperative PCE in our department

    佐々木敬則, 出張裕也, 荻和弘, 岡本準也, 都倉尭明, 大橋伸英, 中井裕美, 土橋恵, 笹谷聖, 加藤大貴, 宮崎晃亘

    日本口腔腫瘍学会総会・学術大会プログラム・抄録集   41st   2023

    　More details

  • 超選択的動注化学療法施行後にコレステロール塞栓症を発症した口底癌の1例

    佐々木 敬則, 都倉 尭明, 岡本 準也, 中井 裕美, 土橋 恵, 笹谷 聖, 荻 和弘, 出張 裕也, 宮崎 晃亘

    日本口腔腫瘍学会誌   34 ( 4 )   183 - 189   2022.12

    　More details

  • Pembrolizumab投与後に心筋炎を発症した舌癌の1例

    都倉 尭明, 佐々木 敬則, 西山 廣陽, 岡本 準也, 出張 裕也, 宮崎 晃亘

    日本口腔外科学会雑誌   68 ( 9 )   385 - 391   2022.9

    　More details

  • 75歳以上の口腔癌患者の治療法決定に影響を及ぼす因子の検討

    中井 裕美, 宮崎 晃亘, 岡本 準也, 土橋 恵, 佐々木 敬則, 荻 和弘, 出張 裕也

    頭頸部癌   48 ( 2 )   236 - 236   2022.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 切除不能な再発口腔扁平上皮癌におけるNotch変異と免疫チェックポイント阻害剤治療効果についての検討

    荻 和弘, 岩本 空大, 笹谷 聖, 中井 裕美, 岡本 準也, 西山 廣陽, 金子 剛, 佐々木 敬則, 出張 裕也, 宮崎 晃亘

    頭頸部癌   48 ( 2 )   217 - 217   2022.5

    　More details

    Language：Japanese   Publisher：(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • Stage III・IVの口腔扁平上皮癌に対する動注化学療法併用放射線治療の治療効果に関する検討

    小池和茂, 岡本準也, 西山廣陽, 佐々木敬則, 荻和弘, 出張裕也, 宮崎晃亘

    頭頸部癌   47 ( 2 )   2021

    　More details

  • A case of SAPHO syndrome diagnosed due to pain after implant treatment

    宮本昇, 宮本昇, 出張裕也, 西山廣陽, 佐々木敬則, 五十嵐友彦, 五十嵐友彦, 志村俊一, 志村俊一, 都倉尭明, 都倉尭明, 中村博幸, 宮崎晃亘

    Japanese Journal of Maxillo Facial Implants   20 ( 4 )   2021

    　More details

  • ハイドロゲル創傷被覆・保護剤エピシルが口腔粘膜炎患者の経口摂取に及ぼす影響

    水野 愛理, 巽 博臣, 佐々木 敬則, 仲 詩織, 荒川 朋子, 藤井 由美子, 石崎 千順, 大原 雄希, 梅森 祥央, 黒川 翔, 秋月 恵美, 信岡 隆幸, 宮崎 晃亘

    学会誌JSPEN   2 ( Suppl.1 )   1492 - 1492   2020.11

    　More details

    Language：Japanese   Publisher：(一社)日本臨床栄養代謝学会  

    Ichushi

    researchmap

  • ハイドロゲル創傷被覆・保護剤「エピシル」が経口摂取に及ぼす影響

    水野 愛理, 種村 理絵子, 高橋 ゆかり, 佐々木 敬則, 荻 和弘, 出張 裕也, 宮崎 晃亘

    日本口腔ケア学会雑誌   14 ( 3 )   198 - 198   2020.9

    　More details

    Language：Japanese   Publisher：(一社)日本口腔ケア学会  

    Ichushi

    researchmap

  • リハビリテーション治療の効果を高める栄養管理-個別対応と組織的対応- 集中治療と、栄養療法と、リハビリテーション治療と ICUとNSTをやってわかったこと

    巽 博臣, 井山 諭, 大槻 郁人, 宮城島 沙織, 清藤 恭貴, 黒川 翔, 大原 雄希, 高橋 和也, 望月 真希, 石原 悦菜, 仲 詩織, 白石 沙耶可, 荒川 朋子, 藤井 由美子, 水野 愛理, 佐々木 敬則, 原田 敬介, 信岡 隆幸, 升田 好樹

    The Japanese Journal of Rehabilitation Medicine   57 ( 特別号 )   S434 - S434   2020.7

    　More details

    Language：Japanese   Publisher：(公社)日本リハビリテーション医学会  

    Ichushi

    researchmap

  • 上顎骨肉腫治療後の顎欠損に対して腓骨再建し広範囲顎骨支持型補綴装置を応用した1例

    宮本昇, 出張裕也, 五十嵐友彦, 佐々木敬則, 佐々木敬則, 志村俊一, 西山廣陽, 都倉尭明, 宮崎晃亘

    Japanese Journal of Maxillo Facial Implants   17 ( 3 )   257   2018.11

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • Diagnosis of prostate cancer with disseminated intravascular coagulation consequent to hemorrhage following tooth extraction: a case report

    佐々木敬則, 宮崎晃亘, 小野公之, 神野由貴, 宮川明, 平塚博義

    日本口腔外科学会雑誌   64 ( 4 )   231‐236 - 236   2018.4

    　More details

  • 網羅的なHLAリガンドーム解析による新規がん幹細胞抗原ペプチドの同定と免疫療法への応用

    宮本昇, 宮本昇, 佐々木敬則, 佐々木敬則, 土橋恵, 土橋恵, 五十嵐友彦, 小林淳一, 荻和弘, 出張裕也, 宮崎晃亘, 平塚博義

    日本口腔腫瘍学会総会・学術大会プログラム・抄録集   36th   190   2018

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 口腔扁平上皮癌に関与する長鎖非コードRNAの同定

    西山 廣陽, 荻 和弘, 都倉 尭明, 佐々木 敬則, 小林 淳一, 宮崎 晃亘, 平塚 博義

    日本口腔科学会雑誌   66 ( 2 )   195 - 195   2017.7

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    researchmap

  • A case of methotrexate‐associated lymphoproliferative disorders simultaneously arising in the maxilla and the nasal mucosa of a patient receiving bisphosphonate

    宮本昇, 宮崎晃亘, 大西みちよ, 佐々木敬則, 島西真琴, 平塚博義

    日本口腔外科学会雑誌   63 ( 4 )   210‐215 - 215   2017.4

    　More details

  • 当科における顎矯正手術に対する低侵襲手術および手術における安全性向上の取り組み

    出張裕也, 佐々木敬則, 五十嵐友彦, 三木善樹, 荻和弘, 宮崎晃亘

    北海道歯科医師会誌   ( 72 )   95‐97   2017.2

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 上顎骨腫瘍摘出後の顎欠損に対して広範囲顎骨支持型補綴装置を応用した1例

    佐々木敬則, 五十嵐友彦, 三木善樹, 荻和弘, 宮崎晃亘, 平塚博義

    北海道歯科医師会誌   ( 72 )   99‐100   2017.2

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 上顎骨腫瘍摘出後の顎欠損に対して広範囲顎骨支持型補綴装置を応用した1例

    佐々木 敬則, 五十嵐 友彦, 三木 善樹, 荻 和弘, 宮崎 晃亘, 平塚 博義

    北海道歯科医師会誌   ( 72 )   99 - 100   2017.2

    　More details

    Language：Japanese   Publisher：(一社)北海道歯科医師会  

    Ichushi

    researchmap

  • 当科における頭頸部癌に対するセツキシマブの使用経験

    小林淳一, 宮崎晃亘, 土橋恵, 中井裕美, 荻和弘, 佐々木敬則, 岡本準也, 中垣貴文, 宮本昇, 平塚博義

    日本口腔腫瘍学会総会・学術大会プログラム・抄録集   35th   187   2017

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 75歳以上の高齢口腔扁平上皮癌患者の臨床的検討

    中井裕美, 宮崎晃亘, 小林淳一, 岡本準也, 土橋恵, 中垣貴文, 宮本昇, 荻和弘, 出張裕也, 佐々木敬則, 平塚博義

    日本口腔腫瘍学会総会・学術大会プログラム・抄録集   35th   184   2017

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 口腔扁平上皮癌に関与する長鎖非コードRNAの同定

    西山廣陽, 荻和弘, 都倉尭明, 佐々木敬則, 小林淳一, 宮崎晃亘, 平塚博義

    日本口腔科学会学術集会プログラム・抄録集   71st   299 - 1292   2017

    　More details

    Language：Japanese   Publisher：(一社)日本癌学会  

    Ichushi

    J-GLOBAL

    researchmap

  • 上顎骨腫瘍摘出後の顎欠損に対して広範囲顎骨支持型補綴装置を応用した1例

    佐々木敬則, 出張裕也, 都倉尭明, 宮本昇, 五十嵐友彦, 宮崎晃亘

    Japanese Journal of Maxillo Facial Implants   15 ( 3 )   208   2016.11

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 下顎関節突起骨折96例の臨床的検討

    小池 和茂, 宮崎 晃亘, 佐々木 敬則, 都倉 尭明, 西山 廣陽, 荻 和弘, 平塚 博義

    日本口腔科学会雑誌   65 ( 2 )   139 - 140   2016.7

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    J-GLOBAL

    researchmap

  • 逆性上顎正中過剰埋伏歯に生じた含歯性嚢胞の1例

    都倉 尭明, 佐々木 敬則, 荻 和弘, 宮崎 晃亘, 平塚 博義

    日本口腔科学会雑誌   65 ( 2 )   188 - 188   2016.7

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    researchmap

  • 口腔扁平上皮癌の発生や進展において重要な役割を果たす長鎖非コードRNAの同定

    西山 廣陽, 竹田 康佑, 中垣 貴文, 都倉 尭明, 佐々木 敬則, 荻 和弘, 宮崎 晃亘, 平塚 博義

    日本口腔科学会雑誌   65 ( 2 )   194 - 194   2016.7

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    researchmap

  • 頸部郭清術を適用した口腔癌一次症例の治療経過

    平塚 博義, 宮崎 晃亘, 仲盛 健治, 安倍 聖人, 荻 和弘, 上田 愛, 佐々木 敬則, 金子 剛, 西山 廣陽, 阪本 結生, 井手 隆

    日本口腔科学会雑誌   64 ( 2 )   109 - 109   2015.7

    　More details

    Language：Japanese   Publisher：(NPO)日本口腔科学会  

    Ichushi

    researchmap

  • A case of phosphaturic mesenchymal tumor mixed connective tissue variant arising in the mandibular gingiva

    DEHARI Hironari, SASAKI Takanori, IGARASHI Tomohiro, KANEKO Tsuyoshi, MIYAZAKI Akihiro, HIRATSUKA Hiroyoshi

    58 ( 2 )   62 - 66   2012.2

    　More details

  • 進行・再発口腔がんに対するsurvivin‐2Bペプチドワクチン療法の第1相臨床試験

    宮崎晃亘, 小林淳一, 山本崇, 鳥越俊彦, 廣橋良彦, 道振義貴, 佐々木敬則, 仲盛健治, 佐藤昇志, 平塚博義

    日本癌治療学会誌   45 ( 2 )   865   2010.9

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • ビスフォスフォネート関連顎骨壊死の臨床的検討

    島西真琴, 出張裕也, 上田愛, 佐々木敬則, 五十嵐友彦, 小野公之, 荻和弘, 安倍聖人, 永井格, 平塚博義

    日本口腔科学会雑誌   59 ( 1 )   61   2010.1

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 下顎第三大臼歯と下顎管との位置関係について―CT画像による評価―

    佐々木敬則, 仲盛健治, 白鳥香理, 安保直樹, 永井格, 平塚博義

    日本口腔科学会雑誌   58 ( 4 )   307   2009.9

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 下顎第三大臼歯と下顎管との位置関係について―パノラマX線写真による頬舌的関係の予測―

    仲盛健治, 佐々木敬則, 安倍聖人, 中井光義, 五十嵐友彦, 平塚博義

    日本口腔科学会雑誌   58 ( 4 )   307   2009.9

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 下顎に発生した低悪性度骨肉腫の1例

    仲盛健治, 佐々木敬則, 道振義貴, 平塚博義

    日本臨床口腔病理学会総会・学術大会プログラム・抄録集   20th   61   2009.7

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 下顎歯肉線維腫が原因であった腫瘍性骨軟化症の1例

    佐々木敬則, 道振義貴, 仲盛健治, 平塚博義

    日本臨床口腔病理学会総会・学術大会プログラム・抄録集   20th   70   2009.7

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • 口蓋の神経線維腫に併発した悪性リンパ腫の1例

    道振義貴, 仲盛健治, 佐々木敬則, 平塚博義

    日本臨床口腔病理学会総会・学術大会プログラム・抄録集   20th   56   2009.7

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • Clinical investigation of bisphosphonate-related osteonecrosis of the jaws

    Hironari Dehari, Kei Tomihara, Megumi Ueda, Makoto Shimanishi, Masayuki Ono, Takanori Sasaki, Tomohiro Igarashi, Kaori Shiratori, Masato Abe, Kazuhiro Ogi, Kenji Nakamori, Akihiro Miyazaki, Itaru Nagai, Hiroyoshi Hiratsuka

    Japanese Journal of Cancer and Chemotherapy   36 ( 13 )   2587 - 2592   2009

    　More details

    Language：Japanese   Publisher：Japanese Journal of Cancer and Chemotherapy Publishers Inc.  

    PubMed

    J-GLOBAL

    researchmap

  • 口腔内血腫により発見され,ステロイド・H.pylori除菌併用療法が著効を示した特発性血小板減少性紫斑病の1例

    仲盛健治, 五十嵐友彦, 佐々木敬則, 中井光義, 道振義貴, 永井格, 平塚博義, 安井寛, 林敏昭, 石田禎夫, 安達正晃

    日本外科感染症学会雑誌   5 ( 5 )   589 - 589   2008.10

    　More details

  • 当科における外傷患者とその治療の推移

    小野公之, 安倍聖人, 冨原圭, 島西真琴, 佐々木敬則, 永井格, 平塚博義

    日本口腔科学会雑誌   57 ( 4 )   526 - 527   2008.9

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

▼display all

Awards

  • 若手研究奨励賞

    2011   日本がん免疫学会  

    　More details

Research Projects

  • Elucidation of the mechanisms relating to immunoregulation in oral tumor microenvironment and development of novel treatments

    Grant number：23H03104  2023.4 - 2026.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    　 More details

    Grant amount：\18980000 （ Direct Cost: \14600000 、 Indirect Cost：\4380000 ）

    researchmap

  • 口腔がん免疫療法に抗NKG2A抗体を併用した新たな機能温存治療の開発

    Grant number：20K18703  2020.4 - 2023.3

    日本学術振興会  科学研究費助成事業 若手研究  若手研究

    佐々木 敬則

    　 More details

    Grant amount：\4160000 （ Direct Cost: \3200000 、 Indirect Cost：\960000 ）

    令和3年度は口腔がん患者の組織検体でHLA-EおよびNKG2Aの免疫染色を行った。現在、解析を行っている。また樹立した癌細胞株のHLA-E発現とTILのNKG2A発現をフローサイトメトリーで確認し、解析を行っている。

    researchmap

  • Basic and clinical study of new peptide vaccine therapy for patients with oral cancer

    Grant number：25463115  2013.4 - 2016.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    Miyazaki Akihiro, KOBAYASHI Jun-ichi, SASAKI Takanori, FUJINO Junki, MICHIFURI Yoshitaka

    　 More details

    Grant amount：\5070000 （ Direct Cost: \3900000 、 Indirect Cost：\1170000 ）

    We described a sequential clinical trial of SVN-2B peptide vaccine therapy in combination with incomplete Freund’s adjuvant (IFA) and interferon (IFN)-alpha for patients with oral cancer. Results indicated that the combination therapy increased the frequency of peptide specific cytotoxic T lymphocytes (CTLs) more effectively than the peptide alone. This regimen may be useful as a new therapeutic modality.
    We isolated oral cancer stem-like cells (CSCs) as aldehyde dehydrogenase 1 bright (ALDH1br) cells. SPRR1B gene was shown to be overexpressed in the ALDH1br cells, indicating that it has a role in cell growth and maintenance by suppression of RASSF4. Furthermore, we established an oral cancer cell line and an autologous CTL line. It was shown that the CTL line recognized autologous tumor cells in an HLA-A24-restricted manner. Precise analyses of the CTL-recognized antigens may provide us with substantial strategies toward developing a more effective cancer peptide vaccine.

    researchmap

  • Development of cancer peptide vaccine therapy for oral cancer

    Grant number：22592242  2010 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    MIYAZAKI Akihiro, YAMAGUCHI Akira, KOBAYASHI Jyunichi, YAMAMOTO Takashi

    　 More details

    Grant amount：\4550000 （ Direct Cost: \3500000 、 Indirect Cost：\1050000 ）

    We have confirmed the safety and efficacy of a cancer peptide vaccine therapy using a survivin2B-derived peptide decomposed from a survivin protein that is highly expressed in many malignancies. Furthermore, a clinical trial indicated that when using the peptide in conjunction with stimulants, a stronger immune effect could be obtained than from the peptide alone. The trial also confirmed the safety of the vaccine therapy. In the quest to develop a cancer peptide vaccine other than survivin, we have identified molecules that are highly expressed in cancer stem cells of the oral cavity, and established a foundation towards a more effective clinical application of cancer peptide vaccine therapy.

    researchmap

  • Analysis of the β catenin gene abnormality and therapeutic application for oral cancer.

    Grant number：22390388  2010 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    HIRATSUKA Hiroyoshi, DEHARI Hironari, MIYAZAKI Akihiro, OGI Kazuhiro, SASAKI Takanori, NAKAMORI Kenji, KOBAYASHI Jyunichi, SOGABE Youhei, YAMAMOTO Takashi, SHIMANISHI Makoto

    　 More details

    Grant amount：\19370000 （ Direct Cost: \14900000 、 Indirect Cost：\4470000 ）

    Hypoxic regions in solid tumors mediate malignant transformation, cancer cell proliferation, resistance to anti-cancer agents, and enhanced cellular invasion and metastasis. In this study, we found that the wnt/β-catenin pathway activation mediates the acquisition of invasion and metastatic potential in oral squamous cell carcinoma cells. Hypoxia enhances the expression of glucose transporter 1 (GLUT1) and anticancer drug resistance, and activates NF-κB/p65 to trigger cell proliferation.

    researchmap